

APPENDIX

The following sites (Principal Investigators) recruited patients into the study: Royal Devon & Exeter Hospital (J Coppel); Queen Elizabeth Hospital, Birmingham (C Craddock), Addenbrookes Hospital, Cambridge (B Huntly), Nottingham University Hospital (J Byrne), Royal Liverpool University Hospital (R E Clark), St James University Hospital, Leeds (G Smith), Freeman Hospital, Newcastle (S G O'Brien), Manchester Royal Infirmary (F Dignan), Birmingham Heartlands Hospital (J Ewing), Salisbury District Hospital (J Cullis), Hammersmith Hospital, London (J Apperley, D Milojkovic), Hereford County Hospital (L Robinson), Churchill Hospital, Oxford (A Mead), King's College Hospital, London (H de Lavallade), Kent & Canterbury Hospital (C Pocock), Colchester General Hospital (G Campbell), Southmead Hospital, Bristol (A Whiteway), Aberdeen Royal Infirmary (D Culligan), University Hospital of Wales, Cardiff (A Goringe), Beatson West of Scotland Cancer Centre, Glasgow (M Copland).

LEGEND for Supplementary material.

Supplementary Table. New patient-reported symptoms during de-escalation, that were not present at trial entry. Grading is according to the National Cancer Institute Common Toxicity criteria.

Symptom	No. of patients	No. of reports	Grade 1	Grade 2	Grade 3/4
Musculoskeletal symptoms	36 (21%)	53	43	10	-
Lethargy	24 (14%)	25	23	2	-
Skin disorders	19 (11%)	22	18	4	-
Nausea/vomiting	16 (9%)	22	18	4	-
Diarrhoea	12 (7%)	13	12	1	-
Hot flushes/sweats	8 (5%)	8	7	1	-
Eye disorders	6 (3%)	7	6	1	-